Menu Search
Equities

Aurisco Pharmaceutical Co Ltd

605116:SHH

Aurisco Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)21.12
  • Today's Change-0.78 / -3.56%
  • Shares traded1.82m
  • 1 Year change-17.40%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Aurisco Pharmaceutical Co Ltd grew revenues 25.24% from 1.01bn to 1.26bn while net income improved 37.23% from 210.90m to 289.42m.
Gross margin57.16%
Net profit margin23.81%
Operating margin27.41%
Return on assets11.23%
Return on equity16.47%
Return on investment13.35%
More ▼

Cash flow in CNYView more

In 2023, Aurisco Pharmaceutical Co Ltd increased its cash reserves by 22.29%, or 75.47m. The company earned 385.61m from its operations for a Cash Flow Margin of 30.54%. In addition the company generated 49.02m cash from financing while 365.27m was spent on investing.
Cash flow per share--
Price/Cash flow per share--
Book value per share5.58
Tangible book value per share5.28
More ▼

Balance sheet in CNYView more

Aurisco Pharmaceutical Co Ltd has a Debt to Total Capital ratio of 30.49%, a higher figure than the previous year's 2.05%.
Current ratio3.90
Quick ratio2.82
Total debt/total equity0.4386
Total debt/total capital0.3049
More ▼

Growth rates in CNY

Year on year, growth in earnings per share excluding extraordinary items increased 35.00%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
Div yield(5 year avg)--
Div growth rate (5 year)--
Payout ratio (TTM)26.23%
EPS growth(5 years)13.31
EPS (TTM) vs
TTM 1 year ago		27.26
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.